(18) was obtained from plasmid B155 (19) as a 1468-bp Dra NMice immunized with this vaccine had an 86% reduction In I-EcoRV fragment. This fragment was ligated into pUC18 liver.stage parasite burden after challenge with 5 x l0s sporothat had been digested with Sinai followed by calf intestinal zoites (>10s median Infectious doses). Eighteen (68%) of 28 alkaline phosphatase, to form pUC18/PyCSP. A 1486-bpXba mice that received two or three doses of vaccine were protected I-Kpn I fragment encompassing the PyCSP gene was excised against challenge with 102 sporozoites, and the protection was from pUC18/PyCSP and used to replace the 666-bp Xba dependent on CD8÷ T cells. These studies demonstrate the I-Kpn I fragment of the human interleukin 2 (IL-2) expres. utility of plasmid DNA immunization against a nonviral infecsion vector pBC12/CMV/IL-2 (20) to form pDIP/PyCSP.1. tion. By obviating the requirement for peptide synthesis, DNA sequencing of the Xba I junction of pDlP/PyCS' 1 expression and purification of recombinant proteins, and adpredicted that the entire CSP coding region was fused ýn juvants, this method of immunization provides an important frame with the sequence encoding the first 82 aa of IL-2. alternative for rapid identification of protective B. and T.cell Plasmid DNA for injections was purified by CsCI gradient epitopes and for construction of vaccines to prevent malaria centrifugation, sterilized by ethanol precipitation, and susand other Infectious diseases.
pended in sterile phosphate-buffered saline (PBS In experiments where CDB* cells were control mice were injected with unmodified plasmid DNA depleted, 0.9 ml of plain medium, 0.01 ml of mAb 2.43 (a mAb lacking the PyCSP gene. Positive control mice were immuto CD8* cells), and 0.1 ml of rabbit complement were added nized i.v. with IrrSpz, 5 x 101 for the first dose and 3 x 104 to pelleted effector cells. After a 20-min incubation, cells were for two subsequent doses (7).
washed and used as effectors in the assay.
Measurement of Antibodies to Spz. To evaluate antibody Protection Against Challenge. Protection against liverresponse after immunization with the plasmid construct in stage infection. Mice that had received three doses of pDIP/ mice, an IFAT and an ELISA were used (2, 7). In the IFAT, PyCSP.1 were challenged i.v. with 5 x 10sPy Spz. Since the diluted sera were allowed to react with air-dried Spz, and median infectious dose (ID.%) for Py Spz is often <2 Spz (10), anti-Spz antibodies were detected with fluorescein-labeled 'his is an enormous challenge, >105 the ID.,o. Forty-two 0 rabbit anti-mouse immunoglobulin. A synthetic peptide, hours later livers were removed, single-cell suspensions were (QGPGAP) 2 , and a recombinant fusion protein, PyCS.1 (2), prepared, and the liver schizonts were counted (26). produced in Escherichia coli that includes aa 64-321 of Protection against blood-stage infection. Immunized mice PCSP were the antigens used in the ELISA. The synthetic were challenged 2-3 weeks after the last immunization by i.v. peptide includes only the major central repeat of PyCSP, injection of 102 Py Spz. Protection was defined as absence of which is the only known target of protective antibodies on Py parasites on blood smears obtained on days 4, 7, 8, 9, 11, p'CSP (2). PyCS.1 contains the authentic major repeat and and 14 after challenge. two minor Py repeat domains and the conserved region 1
Dependence of Protection on CD8÷ T Cells. In additional sequence fused to 81 aa from the nonstructural protein of studies (M.S., unpublished work), the protective efficacy of influenza A (2, 7). To determine whether antibodies were various doses of nkCMVintPyCSP.1 plasmid DNA adminisinduced to the nonrepeat portion of the recombinant protein, a competition ELISA was carried out (2). Various concentered at various intervals fbeen ealuated. Five of 6 mice trationsof(QGPGAP) 2 orofPyCS.Iwereincubatedwiththe administered three doses of 40 •g or 200 pg nkCMimmune sera. The sera were then tested for reactivity with
VintPyCSP.1 at 6-week intervals were protected against PyCS.1 by ELISA as above.
sporozoite challenge. Sixteen days after challenge (30 days
S
To assess the biological activity of the antibodies, the after last immunization), the 10 protected mice were randominhibition-of-liver-stage-development assay (ILSDA) (24) was ized into two groups. On each of the next 3 days, mice in one used. Hepatocytes isolated from mice were seeded in eightgroup received a single intraperitoneal dose of 0.5 mg of the chamber Lab-Tek plastic slides at 105 cells per chamber. After rat IgG2b anti-CD8* (mAb 2.43; ref. 27), and mice in the 24 hr at 37"C in an atmosphere of 5% CO, in air, medium was other group received a control rat IgG2b (mAb J1.2; gift of removed, and 5 x 10' salivary-gland-dissected Spz in 25 p1 of Fred Finkelman (Uniformed Services University of the medium were added, along with 25 pl of various dilutions of Health Sciences) who produced the mAb from a cell line S S sera from immunized or control mice. After 3 hr, the cultures supplied by John Abrams, DNAX). On day 4 the mice were were washed to remove Spz that did not invade hepatocytes, challenged with 102 Spz. and fresh medium was added. At 24 hr the medium was RESULTS AND DISCUSSION changed, and at 48 hr the cultures were fixed and incubated %%ith a mAb directed against liver-stage parasites of Py Antibodies to Spz. Initially, antibody responses were in-(•YLS3) (gift from Y. Charoenvit, Naval Medical Research consistent. After three doses, 9 of 13 mice had antibodies to Institute) before incubation with fluorescein-labeled goat antiSpz, but 7 of these 9 had low levels of antibodies. However, mouse immunoglobulin. Liver-stage schizonts in each culture Table 1 . Antibodies against Spz in mice after immunization wAith were counted with an Olympus UV microscope. The average PyCSP plasmid DNA number of liver schizonts in triplicate cultures was recorded, and percent inhibition was calculated as [ (1 -mean 3 (25)) or no peptide. Targets were labeled with 0. 1 mCi (3.7 Mice were immunized with pDlP/PyCSP.1 at0 and 5 weeks or at 1 of S1Cr (NE2) and incubated at 37C. On the day of 0.5, and 8 weeks. Sera were tested for antibodies to air-dried Spz by iY, targets were washed three times, and various ratios of IFAT(7)5, 8, and 10 weeks after the first immunization. Control mice •elator cells were added to 5000 targets in 96-well U-bottom received the pBC12/CMV/IL-2 plasmid without the PyCSP insert.
Plates. PeptJde was added at 2 pM during the assay. After 6 hr Pooled sera taken 2 weeks after the third immunization with Py 'be Supernatants were harvested (SCS system, Skatron, Ster.
lrrSpz and tested at the same time had an IFAT liter of 1230.
• after four doses, 12 of the 13 mice had moderate to high immunized with IrrSpz ( Table 1) , but had similar levels of I antibody titers (data not shown). To minimize leakage from antibodies against (QGPGAPh2 by ELISA (Fig. 1A) . WI, the injection site, the caliber of the injection needle was suggested that the DNA vaccine was inducing antibodies reduced from 26 to 30 gauge, and the frequency of, _ tibody the central repeat as well as to other epitopes on PyCSP. T, response increased subsequently ( Table 1) .
determine whether the plasmid DNA immunization was To determine whether the antibodies produced by immuinducing antibodies against regions of PyCSP flanking the nization with PyCSP plasmid DNA inhibited invasion of Spz repeats, we performed an ELISA using the recombinant into hepatncytes, serum (IFAT titer, 20,480) from a mouse protein PyCS.Pe. The serum dilution at which absorbance was that had received three doses ofpDIP/PyCSP.1 was tested in 1.0 by ELISA was 7.4 times higher in mice immunized with the ILSDA. This serum inhibted Spz invasion and developpDIP/PyCSP.1 than in mice immunized with IrdSpz ( Fig.  ment by 80 compared with serum from a mouse immunized 1.r), indicating that the plasmid DNA had eliminated the with plasmid control (9.3 "" 2.5 vs. 46.0 "" 3.6 schizonts per imnpnodominance of the central repeats and induced high well; P -0.001, Student's # test, two-tailed). The inhibitory levels of antiboies to the flanking regions. To confirm that activity dropped to 46% when the serum was diluted 1:20.
immunization with pDIP/PyCSP.1 induced antibodies to the Since sera from mice immunized with Py IrrSpz do not inhibit flanking regions, sera from immunized mice were incubated lb Spz invasion and development In this assay (24), the inhib.
with peptide, (QGPGAP)2 or with recombinant protein itory activity of these sra. although low, was encou0raging.
PyCS.1 and then studied in an EUSA for reactivity to However, this relatively poor inhibitory activity was incon-P S.I. The synthetic peptide ( yPGAP)i at 500 QG/ml Ssistent with the extremely high level of antibodies to Spz reduced absorbance by only 5096, while PyCS. I at 15 jug/ml Sobserved by IFAT with these same sera. The only known reduced absorbance to baseline (data not shown). These data on~ (A) andS isC.1 ah rmcmbiar target of protective antio sugest that the poor In vitro biological activity of the central repeat re2ion sequence, (QGPGAd), (2). We to h igheimmz-titer anwt-Spz ser from the plasmid DNA-immunized c afo dy measured antibodies to (QGPGAPo by EmISA. Se mice is due to relatively low levels of antibodies against the Sfrom mice immunized with the PyCSP plasmid DNA had > 10 Important B-cell wpatopes within the ssequence (QGPGAP). times the level of antibodies to sporozomtes as did mice Such data also sugest that the p lasmid DNA auced antibodies play little, if any, role in the protective PyCSP insert (12.7 ± 3.5 vs. 88.0 ± 17.8 schizonts per 1.4 x immunity provided by the vaccine, and that if such vaccines 106 hepatocytes; P = 0.002, Student's t test, two-tailed). are designed to produce protective antibodies, they may have Protection against blood-stage infeciion. In our initial to be constructed to only include DNA sequences coding for challenge experiments, three mice (IA, 2A, and 5A in Table  defined B-cell epitopes. 1) were challenged with 102 Spz and monitored for 14 days.
Genetically Restricted, CD8+ T-Cell-Dependent Cytolytic Two of the three were completely protected (Table 2) . In an Activity After Immunization with PyCSP Plasmid DNA. Imattempt to increase protection, mice were immunized with munization with pDIP/PyCSP.1 induced classical cytolytic threedosesfvaccinebytworegimens (Tabe2)and with activity. The cytotoxicity was genetically restricted, antigen four doses at 0, 8, 10, and 12 weeks. Mice in the three groups specific. and dependent on CD8÷ T lymphocytes. The H.2d
were challenged at 14 weeks. Seven of 13 mice (54%) that effectors did not lyse mismatched EL-4 cells (H-2b) pulsed received three doses of vaccine were protected (Table 2) . with PyCSP-(281-298), P815 cells pulsed with control peptide Antibody levels decreased after the fourth dose in the group PfCSP-(368-390), or P815 cells pulsed with that received four doses, and none of the six mice that after the effectors had been treated with anti-CD8 antibody received four doses were protected (data not shown). Further and complement (Fig. 2) . The cytolytic activity was signifistudies are necessary to determine why the fourth dose cantly greater in mice immunized with pDIP/PyCSP.1 (Fig. caused immunosuppression.
S 2B) than in those immunized with IrrSpz (Fig. 2C) . CD8+ T-Cell Dependence of Protective Immunity. Mice Before achieving consistency of antibody induction by immunized with nkCMVintPyCSP.1 and shown to be promodifying injection techniques, we tested two immunized tected were depleted of their CD8* T cells (97% depletion) or mice without antibodies to Spz and four immunized mice with treated with a control mAb. Thirty-four days after the last antibodies to Spz for CTLs. The mice with antibodies had immunization, the mice were challenged with 102 Spz. Dedemonstrable CTLs (J5-72% specific lysis at 80:1 effector/ pletion of CD8+ T cells eliminated protection in five of five target ratio) whereas the mice without antibodies did not. mice studied, whereas four of the five mice that rcý.eivcd ;he These results suggest that %%hen this vaccine induces immune control mAb were still protected. responses, it induces both antibodies and CTLs.
These studies demonstrate that immunization with PyCSP Protection After in Viro Challenge. Protection against plasmid DNA induces high levels of specific antibodies and liver-stage infection. T) determine whether immunization CTLs and protects against malaria in an extremely rigorous protected against liver-stage infection in vivo, mice that had challenge model system. As after immunization with radiareceived three doses of pDIP/PyCSP.1 and had high IFAT tion-attenuated Py Spz (27) and other PyCSP vaccines (10, titers (mice 3B. 4B. and SB in Table l ) and three mice that had 11), the protective immunity is completely dependent on -. received control plasmid were challenged with 5 x 10W Py CD8÷ T cells, indicating that vaccine-induced CTLs are Spz, and liver-stage infection was assessed 43 hr later. There eliminating infected hepatocytes (28, 29) . The protective was an 85.6 ± 4.0% (mean ± SD) reduction in numbers of immunity induced by immunizing with PyCSP plasmid DNA schizonts in the group that received pDIP/PyCSP.1 as comis not comparable to the sterile immunity against challenge pared with the mice that received the plasmid without the with thousands of Spz induced by immunization with the -10 Effector/taget ratio Effectoq/target ratio" Fzo. 2. Induction ofgenetically restricted. CDS* CTLs against PyCSP by immunization with pDIP/PyCSP.1 and lrrSpz. (A) Two weeks after a third dose of pDIP/PyCSP.1, two mice were euthanized and spleen cells were isolated, stimulated in vitro for S days with peptide PyCSP.(281-296), (SYVPSAEQILEFVKQI), and assessed for cl'tolytic activity (4,9.27). At an effector/target ratio of 60:1, Tcells lysed major histocompatibility complex-matched P815 cells (i-26) pulsed with PyCSP-(281-296) but did not lyse peptide-pulsed EL-4 cells (H-2b). Cytolytic 4-activity was eliminated by depletion of CDS" (CDg') Tcells but was unaffected by depletion of CD4÷ T cells (CD4-) (9). PyCSP-(281-2%) was used to label targets instead oftht H-2Kd.restricted decapeptide SYVPSAEQIL, because we have shown that bulk spleen cultures, in contrast with T-cell clones, more efficiently lyse targets pulsed with the longer peptide (4). (B and C) Mice were immunized with four doses of pDIP/PyCSP.1 (B) or 3 doses of Py lrrSpz (7) (C), and a CTL assay was performed 1I days after the last immunization. Significantly more cytolytic activity against PSIS cells pulsed with the PyCSP-(281-2%) peptide (PyCTL) was demonstrated with cells from mice immunized with pDIP/PyCSP.I. These effectors did not lyse targets pulsed with a control peptide from the P. falciprum CSP, PfCSP (368-390) (KPKDELDY-ENDIEKKICKMEKCS), that includes a CTL epitope (25) and did not lyse P811 cells that had not been exposed to peptide. Cytolysis was dependent on immunization, since spleen cells from naive mice and from mice immunized with the plasmid control and stimulated in vitro with PyCSP-(281-296) had no greater activity against PSIS cells pulsed with PyCSP-(2SI-2.6) than against targets pulsed with the PICSP-(36g-390) control peptide or targets not exposed to peptide (data not shown). S 0 0 0 Moue egme a callng Potcton 3.Rodrigues, M. M., Cordcy, A.-S.. Arreaza, G., Conradin, G., )
